^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK). Add to Collection

    Published date:
    05/29/2020
    Excerpt:
    The ORRs (95% CI) were 75% (34.9-96.8) for pts with ALCL, 70% (34.8-93.3) for IMT and 20% (7.7-38.6) for neuroblastoma....Median DOR was not reached for those with ALCL and IMT.
    DOI:
    10.1200/JCO.2020.38.15_suppl.10505
    Trial ID:
    NCT01742286
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).

    Published date:
    05/29/2020
    Excerpt:
    Ceritinib 750 mg/day under fasted conditions showed antitumor activity in pts with ALK+ ALCL and IMT...
    DOI:
    10.1200/JCO.2020.38.15_suppl.3520
    Trial ID:
    NCT02465528